About this trial

This study aims to evaluate the effect of subthreshold 577 nm micropulse laser photocoagulation in the treatment of initial and refractory cases of Center-Involved Diabetic Macular Edema.

Eligibility criteria

Qualifiers

Age ≥18 years.

Both sexes.

Patients with type 1 or 2 diabetes mellitus (DM), best-corrected visual acuity (BCVA) of 20/400 or better, and center-involved DME [defined as a central macular thickness (CMT) of >250 but <700µm measured by spectral-domain optical coherence tomography].

Patients with any level of non-proliferative diabetic retinopathy or proliferative diabetic retinopathy with adequate panretinal photocoagulation (PRP) and no signs of disease activity determined by fluorescein angiography (FA).

Disqualifiers

Monocular eyes.

Chronic renal failure or renal transplant because of diabetic nephropathy.

Glycated hemoglobin (HbA1c) of more than 10%.

Vitreomacular traction syndrome.

Trial design

Treatments tested in this trial

  • Micropulse Laser

Treatment groups

50 Participants
are divided into 2 treatment groups

Locations

1
the General Authority for Teaching Hospitals and Institutes11562, Cairo Egypt

Sponsors and collaborators

The General Authority for Teaching Hospitals and Institutes

Lead sponsor